![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, July 07, 2016 4:29:49 PM
Posted by Carolyn Dwyer on Jul 7th, 2016
Invivo Therapeutics Holdings Corp
Equities research analysts at Raymond James Financial Inc. started coverage on shares of Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) in a research report issued to clients and investors on Thursday. The firm set a “strong-buy” rating and a $13.00 price target on the stock. Raymond James Financial Inc.’s price objective suggests a potential upside of 127.27% from the stock’s previous close.
Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) opened at 5.72 on Thursday. Invivo Therapeutics Holdings Corp has a 12 month low of $3.50 and a 12 month high of $17.19. The stock’s market capitalization is $182.51 million. The firm’s 50-day moving average is $6.30 and its 200 day moving average is $6.09.
Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) last issued its earnings results on Friday, May 6th. The company reported ($0.20) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.26) by $0.06. During the same quarter last year, the firm earned ($0.24) EPS. On average, equities analysts anticipate that Invivo Therapeutics Holdings Corp will post ($1.07) earnings per share for the current year.
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM